LCN2 and chronic kidney disease: Urine and plasma NGAL have been revealed to be novel biomarkers for diagnosis and outcome prediction in renal dysfunction conditions, including acute kidney injury, chronic kidney disease and renal ischemia-reperfusion injury (24–26).